Malaria vaccine live attenuated - Sanaria

Drug Profile

Malaria vaccine live attenuated - Sanaria

Alternative Names: PfSPZ malaria vaccine live attenuated - Sanaria; PfSPZ Vaccine - Sanaria; Plasmodium falciparum sporozoite vaccine live attenuated - Sanaria; Sanaria PfSPZ Vaccine

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Sanaria
  • Developer National Institute of Allergy and Infectious Diseases; PATH; Sanaria
  • Class Antimalarials; Attenuated vaccines; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Falciparum malaria
  • New Molecular Entity No

Highest Development Phases

  • Phase II Falciparum malaria

Most Recent Events

  • 15 Feb 2017 Efficacy results from the phase I trial in Falciparum malaria (prevention) released by Sanaria
  • 12 Jan 2017 Efficacy results from the phase I trial in Falciparum malaria (prevention) released by Sanaria
  • 01 Nov 2016 Phase-I clinical trials in Falciparum malaria (In adults, In children, In infants, In adolescents, Prevention) in Equatorial Guinea (IV) (NCT02859350)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top